How is Sandhoff Disease diagnosed?

TL;DR: Sandhoff disease is primarily diagnosed through biochemical testing that measures the activity of the hexosaminidase A and B enzymes in blood or skin cells, followed by molecular genetic testing to confirm mutations in the HEXB gene. Because it is a rare, progressive neurodegenerative disorder, definitive diagnosis often requires specialized metabolic testing to distinguish it from other lysosomal storage disorders.

How is a diagnosis of Sandhoff disease confirmed?

The diagnostic process for Sandhoff disease typically begins when a physician observes clinical symptoms such as developmental regression, an exaggerated startle response, or motor weakness. Because Sandhoff disease is a lysosomal storage disorder, the gold standard for diagnosis is a quantitative enzymatic assay. This test measures the activity of hexosaminidase A and B enzymes. In individuals with Sandhoff disease, the activity of both enzymes is severely deficient or absent. Following biochemical confirmation, clinical geneticists will perform molecular genetic testing to identify biallelic pathogenic variants in the HEXB gene, which confirms the diagnosis and provides essential information for family planning.

What is the diagnostic odyssey like for patients?

We recognize the profound frustration inherent in the "diagnostic odyssey" for rare conditions like Sandhoff disease. Families often consult multiple neurologists and pediatricians before a metabolic specialist is involved. Because Sandhoff disease is exceptionally rare, many general practitioners may never encounter a case in their entire career. This lack of familiarity can lead to delayed diagnoses, during which time families often feel unheard or dismissed. It is vital to validate that your search for answers is a rational response to a complex medical situation; seeking a second opinion at a center of excellence is not just encouraged—it is often necessary.

Which medical specialists and tests are involved?

The diagnosis is typically coordinated by a metabolic geneticist or a pediatric neurologist. When clinical suspicion is high, the following diagnostic pathway is generally utilized:

• Enzyme Assay: A blood test (leukocytes) or skin biopsy (fibroblasts) to measure hexosaminidase A and B activity levels.


• Molecular Genetic Testing: DNA sequencing of the HEXB gene to identify specific mutations.


• Ophthalmologic Exam: A retinal exam to check for a "cherry-red spot," a hallmark finding in many sphingolipidoses.


• Neuroimaging (MRI): Used to assess structural brain changes, though it is not diagnostic on its own.

What conditions are in the differential diagnosis?

Sandhoff disease can be clinically difficult to distinguish from other lysosomal storage disorders due to overlapping symptoms. Physicians must carefully differentiate it from:

• Tay-Sachs disease: Tay-Sachs involves only hexosaminidase A deficiency, whereas Sandhoff disease involves both A and B.


• GM1 Gangliosidosis: Often presents with similar neurodegenerative features.


• Niemann-Pick disease: Another lysosomal storage disorder that can present with similar motor and cognitive delays.

Next steps

• Consult a metabolic geneticist or a specialist at a university-affiliated children’s hospital.


• Request a referral to a biochemical genetics laboratory for hexosaminidase enzyme testing.


• Connect with the 44 families in the DiseaseMaps.org community who have navigated this same diagnostic path.


• Ask your physician about genetic counseling to understand the autosomal recessive inheritance pattern of Sandhoff disease.

Medical disclaimer: This information is for educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment; always seek the guidance of a qualified healthcare provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD): Sandhoff Disease.


• Orphanet: Sandhoff Disease (ORPHA:793).


• OMIM (Online Mendelian Inheritance in Man): Hexosaminidase B Deficiency (#268800).


• National Tay-Sachs & Allied Diseases Association (NTSAD).